Get the Stockscreener App
79.34
2.69%
-2.46
Moderna Inc stock is traded at $79.34, with a volume of 4.50M.
It is down -2.69% in the last 24 hours and up +67.79% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$81.80
Open:
$82.1
24h Volume:
4.50M
Relative Volume:
0.62
Market Cap:
$31.45B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-9.7395
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+13.67%
1M Performance:
+67.79%
6M Performance:
+121.79%
1Y Performance:
+166.22%
1-Day Range:
$77.41
$82.90
1-Week Range:
$68.87
$85.60
52-Week Range:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
79.26 | 32.46B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
523.97 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
673.00 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
920.91 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.54 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.62 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Strs Ohio Acquires 68,887 Shares of Moderna, Inc. $MRNA - MarketBeat
RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating - marketscreener.com
Moderna Stock Is Soaring. Is It Too Late to Buy? - The Motley Fool
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna (MRNA) CFO reports RSU vesting, tax-withheld shares on Form 4 - Stock Titan
Moderna (NASDAQ:MRNA) Vaccine Momentum Turns Heads - Kalkine Media
Moderna shares rise as investors continue to digest pipeline expansion and flu vaccine progress - Quiver Quantitative
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Moderna stock hits 52-week high at 81.42 USD - Investing.com
17,700 Shares in Moderna, Inc. $MRNA Bought by Louisiana State Employees Retirement System - MarketBeat
Price to sales forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Jim Cramer Turns Bullish on Moderna After 150% Rally, Citing Cancer Pipeline and Flu Vaccine Momentum - finance.biggo.com
Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” - Yahoo Finance
MRNAModerna Inc Latest SEC Filings - Finviz
Moderna Stock (MRNA) Opinions on mRNA Flu Vaccine Approval and Stock Surge - Quiver Quantitative
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? - The Globe and Mail
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - TradingView
Jim Cramer turns bullish on health care stock after years of doubt - thestreet.com
Moderna (NASDAQ:MRNA) gains $2.9 billion as investors pile into flu push, beating 2025 revenue - TechStock²
Tesla, Rivian, Strategy, Moderna, Sandisk, Blue Owl, and More Stocks That Explain Today’s Market - Barron's
MRNA Stock Surges As Flu Win And CAR-T Hype Fuel Breakout - StocksToTrade
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine - Quiver Quantitative
MRNA Stock Surges As Flu Vaccine Win Fuels Pipeline Hype - StocksToTrade
Moderna COVID-19 Vaccine SpikevaxCompany bets on booster demand in US clinics - AD HOC NEWS
Why Moderna Is Today’s Top S&P 500 Stock - Barron's
The Spikevax Bivalent Original/Omicron COVID-19 VaccineModerna Inc. targets booster demand in the - AD HOC NEWS
Short Squeeze Alert—Moderna Stock Surges on New Strategy - MarketBeat
Pictet Asset Management Holding SA Has $32.79 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Chief Commercial Officer files baseline Form 3 insider statement - Stock Titan
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? - The Globe and Mail
Moderna Inc. mRESVIA targets older adults with a one-dose RSV shot - AD HOC NEWS
ETFs Investing in Moderna, Inc. Stocks - TradingView
mRNA-1273 Linked to Lower COVID-19 Risk Than NVX-CoV2705 - Infectious Disease Advisor
Moderna: Raising Fair Value Estimate Following Science Day That Supports Oncology Pipeline - Morningstar
Moderna Is Applying MRNA Technology in Vaccines, but Also Cancer and Rare Disease Therapies - Morningstar
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines - TradingView
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update - Barchart.com
Stock Of The Day: Will The Moderna Rally Continue? - Benzinga
Moderna (MRNA) Stock Soars 13% on Groundbreaking CAR-T Program Announcement - Blockonomi
Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review - TechStock²
Patton Fund Management Inc. Has $4.49 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Evaluating the 260% Revenue Growth Amidst a Volatile Market - DirectorsTalk Interviews
Moderna Stock Jumps 12% as Pipeline Reset Puts Aug. 5 FDA Catalyst in Focus - FXLeaders
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA - Stocktwits
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week - TechStock²
Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress - Blockonomi
SG Americas Securities LLC Sells 27,930 Shares of Moderna, Inc. $MRNA - MarketBeat
The mRESVIA from Moderna Inc.RSV protection moves beyond Covid - Ad-hoc-news.de
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jun 15 '26 |
Option Exercise |
19.15 |
53,336 |
1,021,384 |
1,537,184 |
| Hoge Stephen | President |
Jun 15 '26 |
Sale |
51.37 |
53,336 |
2,739,870 |
1,483,848 |
0.59%
2.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):